Related Experiment Videos
Inhibition of amphetamine tolerance and metabolism by propranolol
The Journal of Pharmacology and Experimental Therapeutics
|October 1, 1974
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Updates in Small Interfering RNA for the Treatment of Dyslipidemias.
Current atherosclerosis reports·2023
Maternal exposure to air pollutants, PCSK9 levels, fetal growth and gestational age - An Italian cohort.
Environment international·2021
Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance.
Cardiovascular diabetology·2020
HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.
Annals of medicine·2019
A new dawn for managing dyslipidemias: The era of rna-based therapies.
Pharmacological research·2019
ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Expert opinion on pharmacotherapy·2019
A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats.
The Journal of pharmacology and experimental therapeutics·2026
Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed/refractory diffuse large B-cell lymphoma: An exploratory clinical study.
The Journal of pharmacology and experimental therapeutics·2026
Calpeptin and protein kinase C inhibition suppress exosome-associated inflammatory signaling and epidermal dysregulation in a 3-dimensional psoriatic skin model.
The Journal of pharmacology and experimental therapeutics·2026
Adiponectin in cigarette smoke-induced epithelial-mesenchymal transition.
The Journal of pharmacology and experimental therapeutics·2026
CE9A215 (inotodiol) ameliorates oxazolone-induced atopic dermatitis by targeting mast cells and proinflammatory cytokines.
The Journal of pharmacology and experimental therapeutics·2026
Mitochondrial proteomic signatures of postcardiac arrest brain injury reveal potential therapeutic targets.
The Journal of pharmacology and experimental therapeutics·2026
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
Handbook of experimental pharmacology·2026
Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?
The Journal of clinical endocrinology and metabolism·2026
Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.
Immunity, inflammation and disease·2026